HER2 BATs

Phase 2Small molecule

UUniversity of Virginia

HER2 BATs is one of 65 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerNot yet recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

HER2 BATs

UUniversity of Virginia

Phase 2

2 7

Spravato

WWim Janssens

Preclinical

2 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1/2Active, not recruiting

Breast Cancer

NCT03272334

Q2 2032

Phase 1/2Not yet recruiting

Prostate Cancer

NCT07441889

Clinical

Trials by Indication[1]

Breast Cancer2 trials

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Terminated·UUniversity of Virginia·Phase 1·NCT03661424·3 enrolled

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

Active, not recruiting·UUniversity of Virginia·Phase 1/2·NCT03272334·22 enrolled

Prostate Cancer1 trial

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Not yet recruiting·UUniversity of Virginia·Phase 1/2·NCT07441889·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HER2 BATs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HER2 BATs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HER2 BATs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Virginia

HER2 BATs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q2 2032

Trials by Indication[1]

Breast Cancer2 trials

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News